Mohammad Jalali (aka, ‘MJ’) is an assistant professor at Harvard Medical School and a research affiliate with MIT Sloan's System Dynamics Group. Based at MGH Institute for Technology Assessment, MJ uses analytics and simulation-based approaches to help policymakers identify and develop high-leverage policies that not only are effective over the long haul, but also are not thwarted by unanticipated side effects. To achieve this goal, he spends a great deal of time working with decision-makers and policymakers, doing fieldwork and collecting different types of data that can inform richer models and analyses.

MJ’s work has been featured by media outlets, including The New York Times, Washington Post, Associated Press, The Hill, WIRED, Newsweek, Scientific American, Business Insider, Boston Globe, NPR, among others. He has been a reviewer for the National Science Foundation, an associate editor for System Dynamics Review, academic editor for PLOS ONE, and editor for the Journal on Policy and Complex Systems. He is the recipient of the 2015 Dana Meadows Award, the 2015 WINFORMS Excellence Award, and the 2014 Lupina Young Researcher Award. 

Latest News

Fellowship opportunity

April 9, 2020

If you are a recent graduate of a PhD program (or graduating before Sep 2020) from a university in the European Union and are interested in a two-year fellowship to work at my lab, send me your CV and we can discuss more over email. 

Grant application awarded by FDA

September 2, 2019
I’m pleased to share the great news that my grant application to develop a system dynamics model to inform opioid policies has been awarded by the FDA. So proud of my large and interdisciplinary team of amazing researchers from Harvard, MIT, Stanford, Michigan, Wash-St. Louis, Portland State, Northeastern, Homer Consulting, and Ventana Systems.

Grant application awarded by the EU

August 26, 2019
I’m so delighted to share the news that my first grant application (in my new job!) just got accepted by the European Union. This will be a large project (four-year collaboration with eight European countries) for data analysis and modeling to study the quality of life after cancer immunotherapy. The project will start in 2020.
<embed>
Copy and paste this code to your website.